Smith & Nephew (LSE:SN.) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

SN. Overzicht aandelen

Smith & Nephew plc ontwikkelt, produceert, verkoopt en verhandelt samen met haar dochterondernemingen medische hulpmiddelen en diensten in het Verenigd Koninkrijk en internationaal.

Over het bedrijf

SN. fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	4/6
Prestaties in het verleden	2/6
Financiële gezondheid	4/6
Dividenden	3/6

Beloningen

Verhandeld tegen 35.4% onder onze schatting van de reële waarde

De winst zal naar verwachting met 22.71% per jaar groeien

Risicoanalyse

Het dividend van 2.43% wordt niet goed gedekt door de winst of de vrije kasstromen

Heeft een hoog schuldenniveau

Grote eenmalige posten die de financiële resultaten beïnvloeden

Smith & Nephew plc Concurrenten

NIOX Group

AIM:NIOX

UK£284.1m

ConvaTec Group

LSE:CTEC

UK£4.6b

EKF Diagnostics Holdings

AIM:EKF

UK£140.2m

Mediclinic International

LSE:MDC

UK£3.7b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Smith & Nephew
Historische aandelenkoersen
Huidige aandelenkoers	UK£11.51
52 Week Hoogtepunt	UK£12.45
52 Week Laag	UK£8.87
Bèta	0.62
11 maand verandering	-1.12%
3 maanden verandering	9.20%
1 Jaar Verandering	18.34%
33 jaar verandering	-7.44%
5 jaar verandering	-39.63%
Verandering sinds IPO	5,707.03%

Recent nieuws en updates

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Sep 25

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

Aug 08

Recent updates

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Sep 25

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

Aug 08

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 11

Smith & Nephew (LON:SN.) Has A Pretty Healthy Balance Sheet

Aug 19

Investors Could Be Concerned With Smith & Nephew's (LON:SN.) Returns On Capital

Jul 17

Smith & Nephew plc (LON:SN.) Shares Could Be 22% Below Their Intrinsic Value Estimate

Jun 11

Smith & Nephew (LON:SN.) Seems To Use Debt Quite Sensibly

May 09

Smith & Nephew (LON:SN.) Will Want To Turn Around Its Return Trends

Apr 09

Calculating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)

Feb 09

We Think Smith & Nephew (LON:SN.) Can Stay On Top Of Its Debt

Nov 21

Returns On Capital Signal Tricky Times Ahead For Smith & Nephew (LON:SN.)

Nov 08

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 99% Above Its Share Price

Oct 26

These 4 Measures Indicate That Smith & Nephew (LON:SN.) Is Using Debt Reasonably Well

Aug 11

There Are Reasons To Feel Uneasy About Smith & Nephew's (LON:SN.) Returns On Capital

Jul 28

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 58% Above Its Share Price

Jun 26

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Apr 29

Rendement voor aandeelhouders

	SN.	GB Medical Equipment	GB Markt
7D	1.2%	1.1%	0.1%
1Y	18.3%	11.2%	9.7%

Rendement versus industrie: SN. overtrof de UK Medical Equipment industrie, die het afgelopen jaar een rendement 11.2 % opleverde.

Rendement versus markt: SN. overtrof de UK markt, die het afgelopen jaar een rendement opleverde van 9.7 %.

Prijsvolatiliteit

Is SN.'s price volatile compared to industry and market?
SN. volatility
SN. Average Weekly Movement	3.4%
Medical Equipment Industry Average Movement	5.8%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.5%
10% least volatile stocks in GB Market	2.5%

Stabiele aandelenkoers: SN. heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van SN. is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1856	18,000	Deepak Nath	www.smith-nephew.com

Smith & Nephew plc ontwikkelt, produceert, verkoopt en verhandelt, samen met haar dochterondernemingen, medische hulpmiddelen en diensten in het Verenigd Koninkrijk en internationaal. Het bedrijf is actief in drie segmenten: Orthopedie, Sportgeneeskunde & KNO, en Advanced Wound Management. Het bedrijf biedt knie-implantaatproducten voor knievervangingsprocedures; heupimplantaten voor revisieprocedures; trauma- en extremiteitsproducten waaronder interne en externe hulpmiddelen voor de stabilisatie van ernstige fracturen en misvormingscorrectieprocedures; en andere reconstructieproducten.

Smith & Nephew plc Samenvatting

Hoe verhouden de winst en inkomsten van Smith & Nephew zich tot de beurswaarde?
SN. fundamentele statistieken
Marktkapitalisatie	UK£10.04b
Inkomsten(TTM)	UK£229.82m
Inkomsten(TTM)	UK£4.25b

43.7x

Koers/Winstverhouding

2.4x

P/S-verhouding

Is SN. overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SN. resultatenrekening (TTM)
Inkomsten	US$5.64b
Kosten van inkomsten	US$1.67b
Brutowinst	US$3.97b
Overige uitgaven	US$3.66b
Inkomsten	US$305.00m

Laatst gerapporteerde inkomsten

Jun 29, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.35
Brutomarge	70.33%
Nettowinstmarge	5.41%
Schuld/Eigen Vermogen Verhouding	66.7%

Hoe presteerde SN. op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

2.5%

Huidig dividendrendement

107%

Uitbetalingsratio

Betaalt SN. een betrouwbaar dividend?

Zie SN. dividendgeschiedenis en benchmarks

Wanneer moet je SN. kopen om een aanstaand dividend te ontvangen?
Smith & Nephew dividenddata
Ex Dividend Datum	Oct 03 2024
Betaaldatum dividend	Nov 08 2024
Dagen tot Ex-dividend	0 days
Dagen tot dividendbetaaldatum	36 days

Betaalt SN. een betrouwbaar dividend?

Zie SN. dividendgeschiedenis en benchmarks

SN. Overzicht aandelen

Beloningen

Risicoanalyse

Smith & Nephew plc Concurrenten

AIM:NIOX

UK£284.1m

LSE:CTEC

UK£4.6b

AIM:EKF

UK£140.2m

LSE:MDC

UK£3.7b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium)

Smith+Nephew Announces Board and Committee Changes

Upcoming dividend of US$0.14 per share

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

Consensus EPS estimates fall by 16%

Recent updates

Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium)

Smith+Nephew Announces Board and Committee Changes

Upcoming dividend of US$0.14 per share

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

Consensus EPS estimates fall by 16%

First half dividend of US$0.14 announced

First half 2024 earnings: EPS exceeds analyst expectations

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System

Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.).

Consensus EPS estimates increase by 11%

Smith & Nephew (LON:SN.) Will Be Hoping To Turn Its Returns On Capital Around

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Smith & Nephew plc (LON:SN.) Not Flying Under The Radar

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Upcoming dividend of US$0.23 per share

Is Smith & Nephew plc (LON:SN.) Trading At A 30% Discount?

New minor risk - Earnings quality

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Consensus EPS estimates fall by 21%

Final dividend of US$0.23 announced

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Full year 2023 earnings: EPS misses analyst expectations

Capital Allocation Trends At Smith & Nephew (LON:SN.) Aren't Ideal

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Is Smith & Nephew plc (LON:SN.) Trading At A 36% Discount?

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Is Smith & Nephew (LON:SN.) Using Too Much Debt?

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew (LON:SN.) Could Be Struggling To Allocate Capital

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Upcoming dividend of US$0.14 per share at 3.0% yield

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 65% Above Its Share Price

Smith & Nephew (LON:SN.) Has A Pretty Healthy Balance Sheet

Smith & Nephew plc Increases Revenue Guidance for 2023

First half 2023 earnings released: EPS: US$0.20 (vs US$0.20 in 1H 2022)

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Consensus EPS estimates increase by 10%

Investors Could Be Concerned With Smith & Nephew's (LON:SN.) Returns On Capital

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Smith & Nephew plc (LON:SN.) Shares Could Be 22% Below Their Intrinsic Value Estimate

Now 22% undervalued

Smith & Nephew (LON:SN.) Seems To Use Debt Quite Sensibly

Now 20% undervalued

Insider recently bought UK£117k worth of stock

Smith & Nephew (LON:SN.) Will Want To Turn Around Its Return Trends

Upcoming dividend of US$0.23 per share at 2.6% yield

Chief Human Resources Officer recently sold UK£111k worth of stock

Consensus EPS estimates fall by 12%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations